|
|||||
|
|
Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment |
|
| Authors: | Nasim Adabi Safoora Pordel Mohammad Ali Rezaee Fatemeh Sadat Shobeiri Saeideh Sadat Shobeiri |
| Institution: | 1. Department of Biology, Faculty of Basic Sciences, Neyshabour University of Science and Research, Neyshabour, Iran;2. Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Immunology and Allergy, The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran;3. Immunology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;4. Cellular and Molecular Research center, Sabzevar University of Medical Sciences, Sabzevar, Iran |
| Abstract: | Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy approach that has played a tremendous role in the battle against cancer for years. Since the CAR T lymphocytes are unrestricted-major histocompatibility complex T lymphocytes, they could identify more targets than natural T cells, resulting in practical and widespread functions. The good prospects of CAR T-cell therapy in oncology can be additionally applied to treat other diseases such as autoimmune and infectious diseases. CAR-T cell-derived immunotherapy for autoimmune disorders can be allocated to CAR-Tregs and chimeric autoantibody receptor T cells. Other generations of CARs target human immunodeficiency virus (HIV) proteins. In this review, we summarize CAR-T cell therapies in autoimmune disorders and HIV infection. |
| Keywords: | autoimmune diseases CAR-T chimeric antigen receptor cytotoxic T cells human immunodeficiency virus immunotherapy Tregs |